- Home
- FENC vs STRO Comparison
FENC vs STRO Comparison
Compare FENC & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- STRO
- Stock Information
- Founded
- FENC 1996
- STRO 2003
- Country
- FENC United States
- STRO United States
- Employees
- FENC N/A
- STRO N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FENC Health Care
- STRO Health Care
- Exchange
- FENC Nasdaq
- STRO Nasdaq
- Market Cap
- FENC 172.8M
- STRO 172.8M
- IPO Year
- FENC 2001
- STRO 2018
- Fundamental
- Price
- FENC $6.07
- STRO $2.09
- Analyst Decision
- FENC Strong Buy
- STRO Strong Buy
- Analyst Count
- FENC 2
- STRO 7
- Target Price
- FENC $14.00
- STRO $12.14
- AVG Volume (30 Days)
- FENC 173.1K
- STRO 1.4M
- Earning Date
- FENC 11-07-2024
- STRO 11-13-2024
- Dividend Yield
- FENC N/A
- STRO N/A
- EPS Growth
- FENC N/A
- STRO N/A
- EPS
- FENC N/A
- STRO N/A
- Revenue
- FENC $49,348,000.00
- STRO $160,955,000.00
- Revenue This Year
- FENC $97.94
- STRO N/A
- Revenue Next Year
- FENC $11.50
- STRO N/A
- P/E Ratio
- FENC N/A
- STRO N/A
- Revenue Growth
- FENC 278.09
- STRO 230.90
- 52 Week Low
- FENC $3.96
- STRO $2.04
- 52 Week High
- FENC $11.92
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- FENC 61.50
- STRO 28.56
- Support Level
- FENC $5.77
- STRO $2.66
- Resistance Level
- FENC $6.35
- STRO $3.01
- Average True Range (ATR)
- FENC 0.39
- STRO 0.19
- MACD
- FENC -0.02
- STRO -0.04
- Stochastic Oscillator
- FENC 51.62
- STRO 5.64
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.